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Abstract 
Background: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus 
injectable options.
Objectives: To compare patient-reported experiences of fingolimod and dimethyl fumarate.
Methods: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were 
recruited from an online patient community and completed an online survey about treatment side effects, discon-
tinuation, and satisfaction.
Results: 281 patients in four groups completed the survey: currently receiving fingolimod (CF, N = 61), currently 
receiving dimethyl fumarate (CDMF, N = 129), discontinued fingolimod (DF, N = 32) and discontinued dimethyl fuma-
rate (DDMF, N = 59). Reasons for treatment switch were to take oral treatment (CF: 63.3 %, CDMF: 61.8 %), side effects 
of prior medication (CF: 67.3 %, CDMF: 44.1 %) and lack of effectiveness of prior medication (CF: 38.8 %, CDMF: 31.4 %). 
Main reasons for discontinuation were side effects (DF: 46.9 %, DDMF: 67.8 %) and lack of effectiveness (DF: 25.0 %, 
DDMF: 15.3 %). CDMF patients had an increased risk of abdominal pain, flushing, diarrhea, and nausea. Treatment 
satisfaction was highest among CF patients followed by CDMF, DF, and then DDMF patients.
Conclusions: Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate 
were more likely to experience a side effect versus patients currently taking fingolimod. Examination of the relation-
ship between tolerability and adherence/persistence is needed.
Keywords: Relapsing-remitting multiple sclerosis, Fingolimod, Dimethyl fumarate, Treatment discontinuation, Patient 
satisfaction, Side effects
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Background
Multiple sclerosis (MS) is a chronic inflammatory demy-
elinating condition of unknown etiology. It is one of the 
most common diseases of the central nervous system, 
affecting more than 2.3 million people worldwide [1]. 
Approximately 90 % of patients have the relapsing-remit-
ting form of MS (RRMS) initially [1]. With no known 
cure, disease-modifying therapies (DMTs) aim to prevent 
relapses, as well as delay the accumulation of disease bur-
den and disability [2]. From 1993 until recently, DMTs 
approved by the US Food and Drug Administration 
(FDA) were in injectable form, but these have been asso-
ciated with sub-optimal adherence, and increased risk of 
relapse and accumulation of disease burden [3]. Reasons 
for non-adherence include injection-related factors, as 
well as side effects of the medications themselves [4–6].
Fingolimod (Gilenya®, Novartis Pharmaceuticals Cor-
poration) [7], an oral DMT approved by the FDA in 2010, 
has shown to have superior efficacy to a comparator 
injectable DMT [8] and there is evidence of higher adher-
ence and persistence, thought to be attributable in part 
to the improved tolerability profile as well as the mode 
of administration [2, 5]. Although fingolimod is well-tol-
erated, it requires monitoring for 6 h after administering 
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the first dose. Dimethyl fumarate (Tecfidera®, Biogen) 
[9], approved by the FDA in 2013, is another oral DMT 
with favorable efficacy to injectable DMTs [10]. Unlike 
fingolimod, dimethyl fumarate requires no monitor-
ing, but reports suggest it has been challenging for some 
patients to tolerate, particularly within the first 60 days of 
initiating treatment [11].
Tolerability of fingolimod and dimethyl fumarate has 
been assessed in clinical trials and retrospective stud-
ies [2, 5, 12], rather than in less-controlled, real-world 
population studies. This study was designed to explore 
the real-world, patient-reported experiences associ-
ated with initiating treatment with either fingolimod or 
dimethyl fumarate. The specific objectives of this patient-
reported study were to compare the side effect experi-
ences of patients on fingolimod and dimethyl fumarate, 
to compare the levels of treatment satisfaction or dissat-
isfaction between fingolimod and dimethyl fumarate with 
regard to effectiveness, side effects and convenience and 
to describe other patient-reported outcomes related to 
social impact and disability.
Methods
This was a cross-sectional observational study in which 
patients with RRMS in the United States with current or 
past experience of fingolimod or dimethyl fumarate com-
pleted a web-based survey.
Survey development
A draft online survey comprising a battery of measures 
was developed. The first section included questions about 
nine medication-specific side effects representing the 
top five side effects that could be perceived by patients 
for each of the two products based on incidence versus 
placebo as reported in the FDA product labels for each 
product (fingolimod: back pain, cough, diarrhea, head-
ache, influenza; dimethyl fumarate: abdominal pain, diar-
rhea, flushing, nausea, vomiting) [7, 9]. The labelled side 
effect “influenza” was asked of patients in the survey as 
“flu-like symptoms.” All participants were presented with 
the same set of nine side effects.
The treatment satisfaction questionnaire for medica-
tion (TSQM), a 14-item scale measuring patient satisfac-
tion with medication, including side effects, effectiveness, 
convenience, and global satisfaction [13], was admin-
istered. All TSQM scores range from 0 to 100, of which 
higher scores indicate greater treatment satisfaction.
A single item was developed to assess the impact of MS 
on social activities over the past 4 weeks, with five verbal 
response options (‘none of the time’ to ‘all of the time’).
Disability status was assessed using the multiple scle-
rosis rating scale-revised (MSRS-R), a patient-reported 
measure of MS-related functional status that has been 
validated psychometrically [14] and clinically in a 
population of patients with RRMS [15]. The scale cov-
ers the functional domains of “Walking,” “Using arms 
and hands,” “Vision,” “Speaking clearly,” “Swallowing,” 
“Bowel or bladder dysfunction,” “Thinking/Cognition/
Memory,” and “Numbness/Tingling/Burning Sensation/
Pain.” Scores for each scale range from 0 to 4, and the 
Total MSRS-R score ranges from 0 to 32, of which higher 
scores indicate greater disability. Disability was assessed 
using the patient-determined disease steps (PDDS) ques-
tionnaire [16], a 9-level scale providing a score indicating 
the patient-reported level of overall disability, ranging 
from 0 (i.e. normal walking) to 9 (i.e. bedridden).
The draft survey underwent pilot testing in which 
5  patients completed the survey online and partici-
pated in an interview to provide feedback on the clarity 
and appropriateness of instructions, items and response 
options. Based on feedback, minor changes in the word-
ing of items were made to improve clarity or to maintain 
consistency across similar items, and additional response 
options were added to some items to fully capture pos-
sible options.
Study population
Study participants were recruited from an online patient 
community, PatientsLikeMe, a patient-powered research 
network that allows patients with MS to interact, track 
their health data over time, contribute to research [15], 
and improve their self-management [17]. All participants 
in the online community reporting that they had been 
diagnosed with MS by a physician were invited via email 
and provided with a URL to the online screener. Eligibil-
ity criteria included reported diagnosis of RRMS, cur-
rent or past experience of treatment with fingolimod or 
dimethyl fumarate, aged 18 or older, and fluency in Eng-
lish. Any patient who reported they were enrolled in a 
clinical trial was also excluded from participation. Prior 
treatment with other DMTs was permitted. If they met 
the eligibility criteria, participants were presented with 
an online informed consent form, and only those who 
consented proceeded to the online survey. In order to 
have sufficient experience with either medication, par-
ticipants must have been on either treatment for a mini-
mum of 7 days so that patients would have had time to 
experience the product and, for those on fingolimod, to 
have completed the early monitoring phase; anyone who 
had initiated treatment less than 7 days prior to screen-
ing was asked to wait to complete the survey until they 
had been on treatment for at least 7 days. In this case, the 
participant was sent a reminder email after the 8th day of 
treatment to complete the survey. The study protocol was 
approved by New England IRB (Newton, MA). Partici-
pants were not remunerated for taking part in the study; 
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at the end of the study all participants who completed 
the survey were emailed a brief report summarizing the 
findings.
Data analysis
The primary analyses included all eligible participants 
who responded to the survey according to the following 
defined four study groups: participants currently receiv-
ing fingolimod (CF), participants currently receiving 
dimethyl fumarate (CDMF), participants who started 
and then discontinued fingolimod (DF), and those 
who started and then discontinued dimethyl fumarate 
(DDMF). Any patient who fell into more than one group 
based on treatment experience was assigned to a group 
based on his or her most recent treatment experience. 
For example, if a patient discontinued fingolimod and 
dimethyl fumarate, the patient was assigned to a group 
based on the treatment the patient was on most recently.
For each study group (i.e., CF, CDMF, DF, DDMF), 
descriptive statistics, including mean, standard deviation, 
and range for continuous variables, and frequency for 
categorical variables, were generated for medication-spe-
cific side effects of interest, the four scales of the TSQM, 
the single social functioning item, the PDDS question-
naire, the MSRS-R and for demographic and clinical 
characteristics. Descriptive statistics were generated for 
patients in the DF and DDMF groups to summarize char-
acteristics related to therapy discontinuation.
Logistic regression models were employed to deter-
mine the association between study group (CF vs. 
CDMF) and the occurrence of side effects (Yes/No). Due 
to the small number of events observed for some side 
effects, a modification to the logistic regression models 
was implemented in an attempt to minimize potential 
bias due to quasi-complete separation of data. Hence, 
the Firth penalized-likelihood approach was used in all 
logistic regression models so that the issue of small sam-
ple sizes and separation of data points was addressed in 
the analysis [18]. For each side effect, two logistic regres-
sion models were generated: a univariable model and a 
multivariable model that adjusted for age, gender, and 
Total MSRS-R score. Age and Total MSRS-R score were 
included as continuous variables, while gender (male vs. 
female) was included as a categorical variable. Addition-
ally, the occurrence of any side effect (i.e., the indication 
of any of the listed side effects) was also modeled as one 
of the outcomes.
An analysis of variance (ANOVA) model and an anal-
ysis of covariance (ANCOVA) model were utilized to 
determine the association between study groups (CF 
vs. CDMF) and each scale of the TSQM score. In the 
ANOVA model, the only independent variable was 
study group (CF or CDMF). In the ANCOVA model, the 
independent variables were the same as in the multivari-
able logistic regression models. For each study group the 
least-squares mean was presented along with the 95  % 
confidence interval and p value. These same statistics 
were also presented for the difference between study 
groups, and this difference represented the main measure 
of association of study group effect. Because the objec-
tive of this study was not to prove or disprove a specific 
hypothesis, no threshold alpha value was set upon which 
to make a decision of significance. Due to the exploratory 
nature of these analyses, all p values were interpreted as 
descriptive statistics. Sponsorship for this study and arti-
cle processing charges was funded by Novartis Pharma-
ceuticals Corporation.
Results
The survey was fielded from 3 April 2014 to 8 August 
2014. A total of 6256 patients were invited, 470 were 
screened as eligible, 206 were screened as ineligible (per 
inclusion and exclusion criteria) and a total of 283 com-
pleted the survey. Two patients were excluded from the 
analysis because their data indicated they had initiated 
current therapy less than 7  days prior to survey com-
pletion. The final sample sizes for the 281 eligible sur-
vey completers were as follows: CF (N  =  61), CDMF 
(N = 129), DF (N = 32), DDMF (N = 59). Demographic 
and clinical characteristics for the study sample are pre-
sented in Table  1. Overall, observed underlying demo-
graphic and clinical characteristics were generally similar 
across all study groups; however, the sample was gener-
ally overrepresented by the female gender, especially in 
the DF and DDMF subgroups.
Across both current therapy groups, the most com-
monly reported MS medication taken before initiat-
ing current therapy was Copaxone (glatiramer acetate) 
(see Table 2). CF patients were more likely to have taken 
Copaxone as their most recent prior therapy (CF: 27.9 %, 
CDMF: 19.4  %), while CDMF patients were more likely 
to have taken a break from treatment before starting 
dimethyl fumarate (CDMF: 9.3 %, CF: 1.6 %,) or to have 
taken Rebif® (interferon beta-1a) as their most recent 
prior therapy (CDMF: 18.6 %, CF: 8.2 %). Side effects of 
prior medication were cited by 67.3 % of CF and 44.1 % 
of CDMF patients as a reason for switching to current 
therapy. Other commonly reported reasons were: want-
ing to take oral treatment (CF: 63.3  %, CDMF: 61.8  %), 
perceived lack of effectiveness of previous medication 
(CF: 38.8 %, CDMF: 31.4 %), struggling to take previous 
medication as prescribed (CF: 32.7  %, CDMF: 15.7  %), 
and concerns regarding safety of previous medication 
(CF: 28.6 %, CDMF: 27.5 %).
Among the discontinued groups, DDMF patients 
were more likely than DF to indicate side effects as one 
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of the reasons for discontinuing therapy (78.0 vs. 43.8 %, 
respectively) (see Table  3). When asked to provide the 
main reason for discontinuation, the three most common 
responses were side effects (DF: 46.9 %, DDMF: 67.8 %), 
lack of effectiveness (DF: 25.0  %, DDMF: 15.3  %), and 
another reason not listed (DF: 15.6  %, DDMF: 10.2  %). 
Approximately half of the patients in each group indi-
cated that the decision to discontinue therapy was a joint 
decision between the respondent and his or her doctor. 
A slightly greater percentage of DDMF patients (40.7 %) 
reported that the decision was mainly theirs compared 
to DF patients (28.1  %), but the overall distribution of 
responses between groups was similar.
Tolerability
Among the current therapy groups, CDMF patients were 
more likely than CF patients to report abdominal pain, 
diarrhea, flushing, flu-like symptoms, and nausea as 
treatment side effects (see Table 4). The reported occur-
rence of the remaining side effects was similar between 
the two groups. Logistic regression model results sum-
marizing the treatment effect in predicting the occur-
rence of each side effect are presented in Table 5. After 
adjusting for covariates, CDMF patients had an increased 
risk of experiencing abdominal pain (odds ratio, i.e. OR 
15.79), flushing (OR 12.51), and any of the solicited side 
effects (OR 7.49). Results from the univariable model and 
the multivariable model yielded similar results. Other 
side effects for which a pronounced increase in risk was 
observed for CDMF patients after adjustment were diar-
rhea (OR 2.30) and nausea (OR 3.16).
Among patients in the discontinued therapy groups, 
a group effect was observed with DDMF patients more 
than twice as likely to experience the following side 
effects (DDMF vs. DF): abdominal pain (57.6 vs. 15.6 %), 
diarrhea (44.1 vs. 15.6 %), flushing (72.9 vs. 25.0 %), nau-
sea (52.2 vs. 18.8  %), and vomiting (28.8 vs. 6.3  %). The 
reported occurrence of the remaining side effects were 










 Male 14 (23.0 %) 26 (20.2 %) 2 (6.3 %) 8 (13.6 %)
 Female 47 (77.0 %) 103 (79.8 %) 30 (93.8 %) 51 (86.4 %)
Age (years)
 Mean (SD) 46.2 (10.5) 50.4 (9.7) 47.6 (9.5) 51.8 (10.1)
 Min, max 24.0, 65.0 27.0, 72.0 27.0, 66.0 29.0, 72.0
Ethnicity, n (%)
 Hispanic 1 (1.6 %) 1 (0.8 %) 1 (3.1 %) 2 (3.4 %)
 Not hispanic 58 (95.1 %) 124 (96.1 %) 29 (90.6 %) 54 (91.5 %)
 Prefer not to 
answer
2 (3.3 %) 4 (3.1 %) 2 (6.3 %) 3 (5.1 %)
Race, n (%)
 White 53 (86.9 %) 113 (87.6 %) 27 (84.4 %) 53 (89.8 %)
 Black 5 (8.2 %) 8 (6.2 %) 1 (3.1 %) 2 (3.4 %)
 Asian 0 (0.0 %) 1 (0.8 %) 1 (3.1 %) 0 (0.0 %)
 Native American/
Alaska Native
0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (1.7 %)
 Mixed race 3 (4.9 %) 3 (2.3 %) 2 (6.3 %) 2 (3.4 %)
 Prefer not to 
answer
0 (0.0 %) 4 (3.1 %) 1 (3.1 %) 1 (1.7 %)
Disease duration (years)
 Mean (SD) 9.8 (7.7) 11.0 (8.3) 14.8 (9.5) 13.0 (9.6)
 Min, max 0.3, 35.5 0.1, 35.9 2.2, 39.6 0.3, 48.8
Disability according to patient-determined disease steps (PDDS), n (%)
 Normal 16 (26.2 %) 17 (13.2 %) 8 (25.0 %) 4 (6.8 %)
 Mild disability 8 (13.1 %) 21 (16.3 %) 4 (12.5 %) 1 (1.7 %)
 Moderate dis-
ability
8 (13.1 %) 12 (9.3 %) 3 (9.4 %) 10 (16.9 %)
 Gait disability 16 (26.2 %) 20 (15.5 %) 4 (12.5 %) 12 (20.3 %)
 Early cane 4 (6.6 %) 21 (16.3 %) 2 (6.3 %) 12 (20.3 %)
 Late cane 5 (8.2 %) 21 (16.3 %) 5 (15.6 %) 10 (16.9 %)
 Bilateral support 2 (3.3 %) 7 (5.4 %) 4 (12.5 %) 6 (10.2 %)
 Wheelchair/
scooter
2 (3.3 %) 10 (7.8 %) 2 (6.3 %) 4 (6.8 %)
During the past 4 weeks how much has your physical health interfered 
with your social activities?, n (%)
 None of the time 11 (18.0 %) 18 (14.0 %) 3 (9.4 %) 3 (5.1 %)
 A little of the time 18 (29.5 %) 32 (24.8 %) 9 (28.1 %) 10 (16.9 %)
 Some of the time 22 (36.1 %) 46 (35.7 %) 7 (21.9 %) 15 (25.4 %)
 Most of the time 6 (9.8 %) 23 (17.8 %) 9 (28.1 %) 25 (42.4 %)
 All of the time 4 (6.6 %) 10 (7.8 %) 4 (12.5 %) 6 (10.2 %)
Education level, n (%)
 Some high school 0 (0.0 %) 1 (0.8 %) 0 (0.0 %) 0 (0.0 %)
 High school grad 
or GED
5 (8.2 %) 12 (9.3 %) 3 (9.4 %) 8 (13.6 %)
 Some college 26 (42.6 %) 64 (49.6 %) 11 (34.4 %) 25 (42.4 %)
 Undergraduate 
degree
15 (24.6 %) 36 (27.9 %) 8 (25.0 %) 13 (22.0 %)
 Postgraduate 
degree










 Prefer not to 
answer
0 (0.0 %) 1 (0.8 %) 0 (0.0 %) 1 (1.7 %)
Household annual income, n (%)
 Prefer not to say 10 (16.4 %) 30 (23.3 %) 9 (28.1 %) 12 (20.3 %)
 Less than $24,999 10 (16.4 %) 25 (19.4 %) 4 (12.5 %) 10 (16.9 %)
 $25,000–39,999 8 (13.1 %) 15 (11.6 %) 4 (12.5 %) 6 (10.2 %)
 $40,000–79,999 16 (26.2 %) 27 (20.9 %) 4 (12.5 %) 18 (30.5 %)
 80,000 to $119,999 7 (11.5 %) 17 (13.2 %) 5 (15.6 %) 6 (10.2 %)
 $120,000 or more 10 (16.4 %) 15 (11.6 %) 6 (18.8 %) 7 (11.9 %)
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more similar between discontinued therapy groups 
(DDMF vs. DF): back pain (20.3 vs 12.5 %), cough (10.2 
vs. 12.5 %), headache (44.1 vs. 31.3 %), and flu-like symp-
toms (27.1 vs. 21.9 %).
Treatment satisfaction
ANCOVA analyses modeling TSQM scores as a function 
of study group (CF vs. CDMF) are presented in Table 6. 
CF patients on average had better convenience scale 
scores (8.1 points higher than CDMF patients) and bet-
ter side effects scale scores (9.5 points higher than CDMF 
patients). There was no difference between the two 
groups on the “Effectiveness” scale. Differences between 
the groups in the global score indicate a marginal treat-
ment effect related to overall treatment satisfaction 
favoring the CF group.
As expected, treatment satisfaction scores for the dis-
continued therapy groups were lower than the scores for 
the current therapy groups across all TSQM scales. How-
ever, DF patients tended to have higher mean treatment 
satisfaction scores than DDMF patient across all TSQM 
scales: effectiveness (DF: 41.7, SD  =  27.3 vs. DDMF: 
27.3, SD  =  20.4), convenience (DF: 88.9, SD  =  13.5 
vs. DDMF: 79.1, SD  =  20.8), side effects (DF: 81.0, 
Table 2 Characteristics of  patients in  the current fingoli-
mod (CF) and current dimethyl fumarate (CDMF) groups
Characteristic, n (%) CF (N = 61) CDMF (N = 129)
MS medication before taking this therapy
 Copaxone (glatiramer acetate) 17 (27.9 %) 25 (19.4 %)
 Tysabri (natalizumab) 9 (14.8 %) 21 (16.3 %)
 No other med, this was first drug 9 (14.8 %) 14 (10.9 %)
 Tecfidera or Gilenya (Dimethyl Fumer-
ate)
6 (9.8 %) 14 (10.9 %)
 Avonex (interferon beta1a) 6 (9.8 %) 11 (8.5 %)
 Rebif (interferon beta 1a) 5 (8.2 %) 24 (18.6 %)
 Betaseron (interferon beta1b) 5 (8.2 %) 4 (3.1 %)
 Other medicine not listed 2 (3.3 %) 1 (0.8 %)
 No other med, took break from treat-
ment
1 (1.6 %) 12 (9.3 %)
 Aubagio (teriflunomide) 1 (1.6 %) 2 (1.6 %)
 Extavia (interferon beta 1b) 0 (0.0 %) 1 (0.8 %)
Reasons switched to current therapy
 Previous medication side effects
  Yes 33 (67.3 %) 45 (44.1 %)
  No 16 (32.7 %) 57 (55.9 %)
 Wanted to take oral treatment
  Yes 31 (63.3 %) 63 (61.8 %)
  No 18 (36.7 %) 39 (38.2 %)
 Previous medication lack of effectiveness
  Yes 19 (38.8 %) 32 (31.4 %)
  No 30 (61.2 %) 70 (68.6 %)
 Struggled to take previous medication as prescribed
  Yes 16 (32.7 %) 16 (15.7 %)
  No 33 (67.3 %) 86 (84.3 %)
 Concerns regarding safety of previous medication
  Yes 14 (28.6 %) 28 (27.5 %)
  No 35 (71.4 %) 74 (72.5 %)
 Another reason not listed
  Yes 9 (18.4 %) 25 (24.5 %)
  No 40 (81.6 %) 77 (75.5 %)
 Change in health status
  Yes 8 (16.3 %) 24 (23.5 %)
  No 41 (83.7 %) 78 (76.5 %)
 Financial reasons
  Yes 2 (4.1 %) 4 (3.9 %)
  No 47 (95.9 %) 98 (96.1 %)
Table 3 Characteristics of discontinued users
a Participants could select more than one response
Characteristic, n (%) DF (N = 32) DDMF (N = 59)
When did you start therapy?, n (%)
 Within the last 7 days 0 (0.0 %) 1 (1.7 %)
 Between 8 and 30 days ago 0 (0.0 %) 5 (8.5 %)
 Between 31 and 60 days ago 1 (3.1 %) 2 (3.4 %)
 More than 60 days ago 31 (96.9 %) 51 (86.4 %)
When did you stop therapy?, n (%)
 Within the last 7 days 0 (0.0 %) 2 (3.4 %)
 Between 8 and 30 days ago 1 (3.1 %) 14 (23.7 %)
 Between 31 and 60 days ago 3 (9.4 %) 8 (13.6 %)
 More than 60 days ago 28 (87.5 %) 35 (59.3 %)
Reasons stopped taking therapya, n (%)
 Side effects 14 (43.8 %) 46 (78.0 %)
 Doctor advice 8 (25.0 %) 14 (23.7 %)
 Lack of effectiveness in treating MS 8 (25.0 %) 13 (22.0 %)
 Concerns regarding the safety 5 (15.6 %) 5 (8.5 %)
 Struggled to take therapy as pre-
scribed
1 (3.1 %) 3 (5.1 %)
 Financial reasons 1 (3.1 %) 2 (3.4 %)
 Did not want to take oral treatment 0 (0.0 %) 1 (1.7 %)
 Changes to health plan benefits 1 (3.1 %) 0 (0.0 %)
 Another reason not listed 6 (18.8 %) 7 (11.9 %)
Main reason stopped taking therapy, n (%)
 Side effects 15 (46.9 %) 40 (67.8 %)
 Lack of effectiveness in treating MS 8 (25.0 %) 9 (15.3 %)
 Doctor advice 2 (6.3 %) 3 (5.1 %)
 Concerns regarding safety 2 (6.3 %) 0 (0.0 %)
 Financial reasons 0 (0.0 %) 1 (1.7 %)
 Another reason not listed 5 (15.6 %) 6 (10.2 %)
Who mainly made decision to discontinue therapy?, n (%)
 Mainly my decision 9 (28.1 %) 24 (40.7 %)
 Mainly doctor decision 7 (21.9 %) 8 (13.6 %)
 Joint decision 16 (50.0 %) 27 (45.8 %)
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SD = 36.5 vs. DDMF: 49.5, SD = 39.2), global score (DF: 
28.3, SD = 25.1 vs. DDMF: 14.4, SD = 17.5) (results not 
tabulated).
Discussion
This study provides real-world evidence of the toler-
ability and overall treatment satisfaction among patients 
with RRMS using fingolimod and dimethyl fumarate. 
As seen in randomized, controlled trials and clinical 
studies, side effects associated with dimethyl fumarate 
(i.e., abdominal pain, diarrhea, flushing, nausea, vomit-
ing) were more commonly experienced by those in the 
dimethyl fumarate group, supporting other reports of 
the side effect profile of this treatment [11]. However, 
the frequency of side effects associated with fingolimod 
(i.e., back pain, cough, diarrhea, headache, influenza) was 
comparable between groups. Among study participants, 
the odds ratio of experiencing a side effect was approxi-
mately seven, in favor of fingolimod over dimethyl fuma-
rate. Associations remained strong after multivariable 
Table 5 Side effects: logistic regression analyses
a Covariates: age (continuous), gender (male/female), and Total MSRS-R score (continuous)
Side effect Univariable results Multivariable resultsa
Odds ratio  
CDMF vs CF
95 % CI p value Odds ratio  
CDMF vs CF
95 % CI p value
Any side effect 7.11 3.45, 14.62 <0.001 7.49 3.54, 15.86 <0.001
Abdominal pain 14.16 3.77, 53.27 <0.001 15.79 4.20, 59.41 <0.001
Flushing 12.92 6.12, 27.25 <0.001 12.51 5.85, 26.76 <0.001
Nausea 3.28 1.45, 7.40 0.004 3.16 1.38, 7.24 0.007
Flu-like symptoms 3.22 0.81, 12.84 0.097 3.02 0.77, 11.82 0.112
Diarrhea 2.22 1.03, 4.77 0.041 2.30 1.06, 5.00 0.035
Cough 1.33 0.51, 3.48 0.563 1.32 0.50, 3.44 0.574
Vomiting 1.24 0.40, 3.89 0.712 1.26 0.41, 3.91 0.683
Back pain 1.00 0.34, 2.91 0.995 0.94 0.33, 2.72 0.915
Headache 0.85 0.43, 1.67 0.635 0.87 0.43, 1.73 0.687
Table 6 TSQM domain and global scores: ANCOVA analyses
a Covariates: age (continuous), gender (male/female), and Total MSRS-R score (continuous)
b Higher scores indicate higher treatment satisfaction (greater perceived effectiveness, greater satisfaction, fewer/less severe side effects, greater global satisfaction)
c p values are provided as descriptive statistics to assess the degree of difference between each LS mean estimate and zero
TSQM scale ANOVA ANCOVAa
LS meanb 95 % CI p valuec LS meanb 95 % CI p valuec
Effectiveness
 CF 65.2 59.9, 70.5 65.0 59.6, 70.5
 CDMF 66.1 62.5, 69.8 66.2 62.5, 70.0
 Difference −0.9 −7.4, 5.5 0.776 −1.2 −7.9, 5.4 0.720
Convenience
 CF 94.4 90.6, 98.3 94.8 90.9, 98.6
 CDMF 86.8 84.2, 89.4 86.7 84.1, 89.3
 Difference 7.6 3.0, 12.3 0.001 8.1 3.4, 12.8 <0.001
Side effects
 CF 91.6 85.6, 97.5 91.3 85.3, 97.3
 CDMF 81.6 77.8, 85.5 81.8 77.9, 85.6
 Difference 10.0 2.8, 17.1 0.007 9.5 2.3, 16.8 0.010
Global
 CF 76.0 70.2, 81.8 75.5 69.7, 81.4
 CDMF 68.8 64.8, 72.8 69.0 65.0, 73.0
 Difference 7.2 0.1, 14.2 0.047 6.5 −0.6, 13.7 0.076
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adjustment for age and disability, including after a sec-
ond multivariable model adjusting for PDDS instead of 
MSRS-R as the measure of disability.
For both treatment groups, discontinuation was com-
monly driven by the experience of side effects. This was 
particularly evident for dimethyl fumarate, with 68 % of 
patients reporting “experience of side effects” as the main 
reason for discontinuation, and more patients in this 
group deciding unilaterally to stop treatment. Discon-
tinuation of fingolimod was more frequently reported to 
result from a lack of perceived efficacy (25 %) than dime-
thyl fumarate (15 %). Compared to patients taking dime-
thyl fumarate, those currently taking fingolimod were 
more satisfied with treatment overall and specifically 
with regard to side effects and convenience. This was also 
true among the discontinued patients, with those who 
had discontinued fingolimod reporting greater treatment 
satisfaction than those who had discontinued dimethyl 
fumarate. However, perception of treatment effective-
ness was similar between the dimethyl fumarate and fin-
golimod groups and use of the former drug appeared to 
be twice as frequent in this sample. After adjusting for 
underlying group characteristics, the similar perceived 
efficacy remained the same.
Studies in diseases involving long-term treatments 
have shown an association between side effects and poor 
compliance [19–21]. Additionally, studies among MS 
patients have shown that increased adherence leads to 
better patient outcomes and reduced healthcare utiliza-
tion [5, 22, 23]. Thus, DMTs with better tolerability have 
the potential to improve outcomes and reduce resource 
use for RRMS patients, as a result of increased adherence.
Despite the consistency of results, there are several 
limitations of the study that should be noted. The small 
sample sizes did not allow for the detection of potential 
trends between the treatment groups. Although other 
oral DMTs such as teriflunomide (Aubagio®, Biogen) 
have recently been approved for use in RRMS, this study 
was limited to the two DMTs most commonly used at the 
time on PatientsLikeMe. Because accurate data were not 
publicly available to describe the true demographics of 
this subset of the MS population, it was not possible to 
use benchmark weighting to try to control for such dif-
ferences. Additionally, many patients had started therapy 
several months before completing the survey, and given 
that all data was patient-reported, there is the potential 
for recall error regarding medication use, the side effects 
experienced or reasons for discontinuation. Those who 
agreed to participate might not be representative of the 
population of RRMS patients at large, who may not use 
internet, health-sharing sites, nor complete online sur-
veys. Finally, the cross-sectional study design limited the 
ability to ascertain how the side effect experience may 
affect longer term adherence or prognostic outcomes.
In conclusion, the patient experience of fingolimod and 
dimethyl fumarate was similar for some measures and 
favored fingolimod for others. Future research involving 
a larger sample and a longitudinal design would be useful 
to provide further insights on real-world patient experi-
ences and to examine the relationship between tolerabil-
ity and adherence/persistence.
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